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Several investigations have reported that mice administered paraquat dichloride (PQCl2) by intraperito-
neal injection exhibit a loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc). In this
study, male and female C57BL/6J mice were administered PQCl2 in the diet at concentrations of 0 (con-
trol), 10, and 50 ppm for a duration of 13 weeks. A separate group of mice were administered 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) during week 12 as positive controls to produce a loss of dopa-
minergic neurons in the SNpc. The comparative effects of PQ and MPTP on the SNpc and/or striatum were
assessed using neurochemical, neuropathological, and stereological endpoints. Morphological and stere-
ological assessments were performed by investigators ‘blinded’ to the origin of the tissue. Neither dose of
PQCl2 (10 or 50 ppm in the diet) caused a loss of striatal dopamine or dopamine metabolite concentra-
tions in the brains of mice. Pathological assessments of the SNpc and striatum showed no evidence of
neuronal degeneration or astrocytic/microglial activation. Furthermore, the number of tyrosine hydrox-
ylase-positive (TH+) neurons in the SNpc was not reduced in PQ-treated mice. In contrast, MPTP caused a
decrease in striatal dopamine concentration, a reduction in TH+ neurons in the SNpc, and signiﬁcant path-
ological changes including astrocytic and microglial activation in the striatum and SNpc. The MPTP-
induced effects were greater in males than in females. It is concluded that 13 weeks of continuous dietary
exposure of C57BL/6J mice to 50 ppm PQCl2 (equivalent to 10.2 and 15.6 mg PQ ion/kg body weight/day
for males and females, respectively) does not result in the loss of, or damage to, dopaminergic neurons in
the SNpc.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Parkinson’s disease (PD) is a progressive neurodegenerative dis-
order that is typically characterized by motor symptoms (tremor,
bradykinesia, rigidity, and postural instability) that are attributed
to the degeneration and death of dopaminergic neurons in the sub-
stantia nigra pars compacta (SNpc). MPTP (1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine) has been used as an animal model ofPD because it causes dopaminergic neuronal cell death and the loss
of dopaminergic neurons in the SNpc (Jackson-Lewis et al., 1995,
2012; Jackson-Lewis and Smeyne, 2005). The non-selective herbi-
cide paraquat (1,10-dimethyl-4,40-bipyridinium; PQ) has also been
considered by some (Nistico et al., 2011; Ossowska et al., 2005),
but not others (Miller, 2007; Richardson et al., 2005), to be a suit-
able animal model of PD. PQ appears to be structurally similar to
the MPTP metabolite and proximate toxicant MPP+, and by the
use of stereological techniques, several investigators (Brooks
et al., 1999; Gollamudi et al., 2012; Jiao et al., 2012; McCormack
et al., 2002; Peng et al., 2004; Yin et al., 2011) have reported that
PQ administered via the intraperitoneal (ip) route causes a loss of
tyrosine hydroxylase-stained dopaminergic neurons in the SNpc,
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an inability to replicate this ﬁnding (Breckenridge et al., 2013). Fur-
thermore, an intensive, ‘‘blinded’’ neuropathological evaluation did
not ﬁnd any evidence of PQ-induced cell death in multiple brain re-
gions, including the SNpc and striatum, as indicated by an absence
of silver staining of neurons, indicators of apoptosis, or evidence of
glial or astrocytic activation (Breckenridge et al., 2013).
In the majority of studies that evaluated the neurotoxicity of
PQ, the chemical was administered by ip injection, typically once
weekly for several weeks. The systemic exposure to PQ after ip
administration does not reﬂect human exposure in normal agricul-
tural use of PQ (Lock and Wilks, 2001). It is generally accepted that
spray operators using PQ are likely to experience the greatest
exposure to PQ in an agricultural setting. Worker exposure studies
have shown that the dermal route dominates human exposure in
PQ user scenarios, whether these exposures involve applications
by knapsack (Chester and Woollen, 1982; Staiff et al., 1975; Van
Wendel de Joode et al., 1996), applications by tractor (Forbess
et al., 1982; Staiff et al., 1975; Wojeck et al., 1983), or by aircraft
(Chester and Ward, 1984). However, mouse skin poorly replicates
the absorption characteristics of human skin, being at least two or-
ders of magnitude more permeable to PQ (Scott et al., 1986). Chui
and associates (Chui et al., 1988) have shown that in the rodent an
oral (gavage) dose and a dermal dose both result in a peak PQ con-
centration in blood 40–60 min after dosing, whereas an ip dose re-
sults in a peak PQ concentration in blood at 12–15 min post dose
(Breckenridge et al., 2013). Since it is difﬁcult to mimic the dermal
route of exposure over a prolonged period using mice, we have
chosen the oral route of exposure as this provides a convenient
measurable dose level and leads to prolonged systemic exposure
analogous to that achieved by the slow absorption of PQ through
the skin. The use of a 13 week dietary study to assess safety in pes-
ticide application scenarios also follows conventional regulatory
practice.
In the present study, mice were exposed to PQCl2 at dietary
concentrations of 10 or 50 ppm for 13 weeks. Achieved dose levels
at 50 ppm were 10.2 mg and 15.6 mg PQ ion/kg body weight (bw)/
day, and the predicted maximum PQCl2 concentrations in the
brain were 416 and 655 ng/g tissue, for males and females, respec-
tively. The mice exposed to PQCl2 in their diets showed no loss of
striatal dopamine or dopamine metabolite concentrations, no evi-
dence of neuronal degeneration or astrocytic/microglial activation,
and no reduction in the number of tyrosine hydroxylase-positive
(TH+) neurons in the SNpc. A group of mice treated with MPTP
served as a positive control to validate the various assessments
used in this study to detect neurotoxic insult.Methods
Dietary kinetic study
Prior to the assessment of neurotoxicity, a preliminary study
was conducted at Charles River Laboratories (UK) in compliance
with Good Laboratory Practice Regulations to determine brain PQ
concentrations in mice following dietary exposure. Groups of male
and female C57BL/6J mice were provided PQCl2 as a dietary admix
for up to 13 weeks to investigate PQ brain and plasma kinetics. The
PQCl2 concentration in each diet was adjusted weekly (based on
mean body weight and food consumption data) to achieve target
dose levels of either 0.3 or 1.5 mg PQCl2/kg bw/day. A subgroup
of high-dose mice were used to assess PQ brain and plasma kinet-
ics during 8 weeks of recovery subsequent to 13 weeks of dietary
PQ treatment. Dietary formulations were prepared using a certiﬁed
rodent diet (Rat and Mouse [modiﬁed] Diet No. 1 SQC expanded
[Ground], Special Diets Services, Stepﬁeld, Witham, UK). At eachsample collection time point (7, 56, and 90 days at both dose lev-
els; and 120 and 150 days at the high-dose level only) a potassium
EDTA blood tube was used to collect a 300 lL blood sample from
each mouse via the saphenous vein. Plasma was obtained from
each sample following centrifugation. Following euthanasia by cer-
vical dislocation, the brain was collected and weighed. Brain and
plasma samples (n = 4 mice/sex/group at each time point) were
stored at 20 C, and subsequently analyzed for PQ content by
HPLC-MS/MS.
To compare the brain concentrations achieved in the dietary
study to studies in which the ip route was used, a PBPK model
based on earlier work (Breckenridge et al., 2013) was used to sim-
ulate a 13 week dietary exposure to PQ in male and female mice.
Physiological parameters for the mouse were taken from Brown
and associates (Brown et al., 1997). Food intake was simulated
using the hourly fraction of diet ingested (Yuan, 1993). Body
weight, reported on a weekly basis, was input as a linear interpo-
lation between each week over the course of the study. The daily
ingested dose was determined based on the weekly reported expo-
sure (mg/kg bw/day), and was kept constant over the 7 day period.
The simulation of dietary intake was used to produce time-course
concentrations expressed as ng/g or ng/mL of PQCl2 in brain and
plasma, respectively. Both the dietary kinetic study and the neuro-
toxicology study were simulated in this way. Simulations of the
dietary kinetic study were compared to simulations of ip dosing,
as ip injection is the most commonly used route in studies of PQ
neurotoxicity. The total systemic PQ dose resulting from the ﬁrst
7 days of dietary dosing was estimated using the PBPK model,
and was divided by seven to give the daily ip dose to be simulated.
Dietary neurotoxicity study
Study conduct
The 13 week dietary study was conducted in the AAALAC-
accredited (Association for Assessment and Accreditation of
Laboratory Animal Care International) laboratory of WIL Research
(Ashland, OH) in compliance with Good Laboratory Practice
Regulations (Organisation for Economic Co-operation and Develop-
ment [OECD], 1998; US Environmental Protection Agency [EPA],
1989). Brain neurochemistry investigations were performed by
RTI International (Research Triangle Park, NC). Microscopic slides
of brain sections for pathology evaluation were prepared by Neuro-
science Associates (NSA), Inc. (Knoxville, TN) and examined by a
pathologist at Tox Path Specialists, LLC (Frederick, MD); both NSA
and the pathologist were ‘‘blinded’’ to treatment group. Brain
tissues for stereological investigations were prepared and evalu-
ated by a stereologist at Experimental Pathology Laboratories
(EPL, Sterling, VA), who was also ‘‘blinded’’ to treatment group.
Study design
The control and test diets were offered continuously for
13 weeks (91–95 consecutive days). Mice were assigned to four
treatment groups (control, 10 ppm PQCl2, 50 ppm PQCl2, and
MPTP). Control and MPTP groups were provided a basal diet for
the duration of the study. PQCl2 was administered in the diet as
a constant concentration of either 10 or 50 ppm. These dietary con-
centrations of 10 and 50 ppm were selected to achieve dose levels
of at least 1.2 and 6.0 mg (ion)/kg bw/day, respectively, over a
90 day period. These two doses were adequately spaced to allow
the observation of any potential dose response, and the top dose le-
vel was expected not to exceed the maximum tolerated dose for
mice of this strain.
MPTP was administered 7 days prior to scheduled euthanasia
(at the beginning of week 12) as four successive ip injections; each
at a dose of 10 mg (free base)/kg bw, spaced at approximately 2 h
intervals. This dose route and dosing regimen have been shown to
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dopaminergic pathway (Breckenridge et al., 2013; Jackson-Lewis
and Przedborski, 2007). The dose volume for the MPTP group
was 2.5 mL/kg bw/dose; individual doses were based on the most
recently-recorded body weights.
Preparation of paraquat diets
Diets were prepared with PQCl2 having a 99.9% purity (Syngen-
ta, Lot Number ASJ10083-03). Prior to use, the PQCl2 was dried in
an oven set at approximately 100 C for a minimum of 4 h. The
50 ppm dietary formulation was prepared by adding PQCl2 to
the powdered diet (PMI Nutrition International, LLC Certiﬁed Ro-
dent LabDiet 5002) and mixing with a blender. A portion of the
50 ppm test diet was then diluted with additional basal diet to ob-
tain the 10 ppm dietary formulation. The test diets were prepared
at approximately weekly intervals. Analysis of dietary samples col-
lected at various intervals throughout the study indicated that die-
tary PQCl2 concentrations ranged from 91.5% to 116% of the target
concentrations.
Preparation of MPTP dosing solution
MPTPHCl was obtained from Sigma–Aldrich, Inc., St. Louis, MO
(Batch Number 090M1522V) and stored at room temperature.
MPTPHCl was formulated as a solution in physiological (0.9%) sal-
ine at 4.0 mg (free base)/mL. The concentration of MPTP was veri-
ﬁed by HPLC to be 103% of the target concentration.
Test animal/animal husbandry
Male and female C57BL/6J mice, 7 weeks of age, were supplied
by Jackson Laboratories, Bar Harbor, ME. Mice were housed in indi-
vidual, stainless-steel, wire-mesh-ﬂoored cages. Individual body
weight and food consumption data were recorded weekly for all
animals. A 12-h light–dark photoperiod was maintained through-
out the study; room temperature and relative humidity were
maintained at 22 ± 3 C and 50% ± 20%, respectively. One week
prior to initiation of PQ treatment, the mice were randomly as-
signed to control and treatment groups using a randomized block
design, stratiﬁed by weight. Treatment with PQ (or basal diet) com-
menced at 10 weeks of age, and MPTP administration occurred
when the mice were 22 weeks of age.
Striatal neurochemistry
During week 13, mice designated for striatal neurochemistry
(n = 6 mice/sex/group) were euthanized by cervical dislocation, fol-
lowed by decapitation and brain removal. The striatal tissue was
isolated, weighed, and ﬂash-frozen in liquid nitrogen. Striatal con-
centrations of dopamine (DA), 3,4-dihydroxyphenylacetic acid
(DOPAC), and homovanillic acid (HVA) were determined by HPLC
coupled with electrochemical detection, as described previously
(Breckenridge et al., 2013). Dopamine turnover was calculated
([DOPAC + HVA]  [DA]).
Striatal and SNpc neuropathology
Control, 10 ppm PQCl2, and 50 ppm PQCl2 mice designated for
neuropathology assessment were euthanized after 31, 59, or
94 days of exposure (n = 5 mice/sex/group/interval). MPTP mice
designated for neuropathology assessment (n = 5 mice/sex) were
euthanized during study week 13 (7 days following MPTP treat-
ment). Mice were anesthetized (sodium pentobarbital ip) and per-
fused in situ with 25 mL of sodium cacodylate buffer, followed by
perfusion with 75 mL of sodium cacodylate-based 4% paraformal-
dehyde (methanol free). The heads were placed in cacodylate-
based 4% paraformaldehyde for 24 h. The brains were then
removed from the skulls, placed into the sodium cacodylate buffer
solution, and maintained refrigerated. The brains were shipped
to Neuroscience Associates, Inc., where they were trimmed,multi-embedded, and sectioned at 30 lm in the coronal plane. Se-
rial sections were produced and stained using amino cupric silver
(Am Cu Ag) stain for neuronal necrosis (de Olmos et al., 1994);
tyrosine hydroxylase (TH) immunostain for dopaminergic neurons
and processes [antibody source: Pelfreez (#P40101) at a 1:6000
dilution]; glial ﬁbrillary acidic protein (GFAP) immunostain for
astrocytes [antibody source: Dako (#Z0334) at a 1:20,000 dilu-
tion]; ionized calcium binding adaptor molecule 1 (IBA-1) immu-
nostain for microglia [antibody source: Wako (#019-19741) at a
1:15,000 dilution]; caspase 3 immunostain (SNpc region only) for
apoptosis [antibody source: Cell Signaling (#9661) at a 1:15,000
dilution]; thionine nissl stain for general morphology; or terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) stain
for apoptosis [ApopTag Peroxidase kit, Millipore #S7101], as previ-
ously described (Breckenridge et al., 2013). All slides were shipped
to Tox Path Specialists, LLC for examination. Microscopic examina-
tion was performed in a ‘‘blinded’’ manner; the pathologist was not
aware of the treatment group to which the individual mouse brain
sections belonged. Neuropathology data were recorded according
to a semi-quantitative scoring system, as previously described
(Breckenridge et al., 2013), including analysis for the presence of
necrotic cells, the character of any glial reaction, an assessment
of the degree of dopaminergic neuron loss (if any), and an assess-
ment of the possible mechanism for the loss.
SNpc stereology
After 91–94 days of exposure, mice designated for stereological
assessment of the number of TH+ neurons in the SNpc (20 mice/
sex/group) were anesthetized (sodium pentobarbital ip) and per-
fused in situ with chilled 0.9% physiological saline, followed by
4% paraformaldehyde (pH approximately 9.5), using a ﬂow rate
of approximately 10 mL/min. The perfusion-ﬁxed brains (including
olfactory bulbs) were preserved in 4% paraformaldehyde, and then
shipped to Experimental Pathology Laboratories, Inc. for further
processing, sectioning, staining, and stereological assessment, as
described by Breckenridge and associates (Breckenridge et al.,
2013). Immunostaining of dopaminergic neurons was performed
according to the standard avidin–biotin complex (ABC) method
[primary antibody: polyclonal anti-tyrosine antibody of rabbit ori-
gin (EMD Millipore, Billerica, MA) at a 1:1000 dilution; secondary
antibody: biotinylated goat anti-rabbit IgG (Vector Laboratories,
Inc.) at a 1:1000 dilution]. The stereological assessment was per-
formed in a ‘‘blinded’’ manner (i.e., the investigator was not aware
of the treatment group).
The total number of TH+ neurons in the SNpc was estimated
using the optical fractionator approach (West et al., 1991), which
employed an unbiased systematic random sampling methodology.
Accordingly, neuron cell bodies were counted in a subsample of
sections, section thicknesses, and section areas, and then the re-
sults were extrapolated to provide estimates of total numbers of
TH+ neurons in the left and right SNpc. The following stereological
parameters were used in this study: section sampling fre-
quency = one of three SNpc containing sections; counting frame
interval = 120  120 mm; counting frame size = 60  60 lm; dis-
sector height = 4 lm; and upper guard zone = 2 lm.
Statistical analysis
The effects of treatment on the concentrations of dopamine,
dopamine metabolites (DOPAC, HVA), and dopamine turnover
were analyzed using ANOVA. When the ANOVA analysis revealed
signiﬁcant (p < 0.05) intergroup variance, Dunnett’s test (Dunnett,
1964) was used to compare the values from PQ and MPTP groups
to the negative control group values.
The effects of treatment (PQ or MPTP) on the mean number of
dopaminergic neurons in the substantia nigra pars compacta (SNpc),
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sided t-test. Differences in means were considered statistically sig-
niﬁcant at p 6 0.05.
Group mean scores based on the categorical classiﬁcation of
microscopic ﬁndings were calculated by Tox Path Specialists, LLC,
but statistical analyses were not conducted.Fig. 2. Modeled PQ brain concentrations at 10 and 50 ppm over 13 weeks. Based on
the modeling of the dietary kinetic study, as well as the body weight and food
consumption data from the neurotoxicity study, the achieved brain PQCl2
concentrations over the exposure period were estimated for male and female mice
treated with diet containing PQCl2 at 10 or 50 ppm.Results
Paraquat kinetic study
The average doses over 90 days in the kinetic study were within
2% of the target doses of 0.3 and 1.5 mg/kg bw/day. PQ brain kinet-
ics in male and female mice were not signiﬁcantly different, so the
mean brain PQ concentrations of the two sexes were combined, as
shown in Fig. 1. Based on earlier work (Breckenridge et al., 2013), a
PBPK model was used to simulate the kinetic study. Simulated PQ
brain concentrations were close to the measured values (Fig. 1).
The model predicted that the concentration of PQ in the brain
would reach a plateau level by the end of 90 days of dosing. After
the mice were transferred to control diet, the PQ residue in the
brain declined exponentially, with a PQ half-life of approximately
21 days.
Daily ip doses were simulated, with a dose level set to achieve
the same total systemic PQ dose as 24 h of dietary dosing. The
mean predicted plasma PQ concentrations were similar for the
two dose routes, but the maximum (peak) plasma concentration
achieved from ip dosing was 24-times greater than the concentra-
tions resulting from dietary dosing.
Dietary neurotoxicity study – paraquat
Achieved paraquat dose levels
The mean dose levels achieved during the 13 week study for the
10 and 50 ppm PQCl2 groups were 2.4 and 14.1 mg/kg bw/day for
males, and 3.7 and 21.5 mg/kg bw/day for females, respectively.
The corresponding doses expressed as PQ ion were 1.7 and
10.2 mg/kg bw/day for males, and 2.7 and 15.6 mg/kg bw/day for
females, respectively.
Based on the successful simulation of brain PQ concentrations
in the kinetic study, as described above, the PBPK model was used
to predict the brain PQ concentrations in the dietary neurotoxicityFig. 1. Brain PQ concentrations in a 13 week kinetic study at dietary dose levels of
0.3 and 1.5 mg/kg/day. Dietary PQCl2 concentrations were adjusted weekly to
maintain achieved dose levels at 0.3 and 1.5 mg/kg bw/day. Brains were collected
after 7, 56, and 90 days of exposure, and after 30 and 90 days of recovery (n = 3–4
brains/interval/dose level). The curves are PBPK model predictions, which take into
account the measured body weight and food consumption data from the study.study (Fig. 2). The predicted maximum PQCl2 concentrations in
the brain during the neurotoxicity study were 416 and 655 ng/g
tissue at the 50 ppm dose level, and 78 and 125 ng/g tissue at
the 10 ppm dose level, for males and females, respectively.Paraquat effects on body weights, food consumption, and clinical
observations
Effects of PQ noted during treatment were limited to a statisti-
cally-signiﬁcantly (p < 0.01) lower mean body weight gain for the
50 ppm PQCl2 males (0.1 g), as compared to control males
(0.6 g), over the ﬁrst week of test diet exposure. Thereafter, there
were no treatment-related ﬁndings based on the parameters as-
sessed in this study.Effects of paraquat on striatal neurochemistry
There were no PQ-related effects on striatal dopamine concen-
trations, dopamine metabolite (DOPAC and HVA) concentrations,
or dopamine turnover (Fig. 3). Based on a lack of a dose–response
pattern, none of the differences relating to HVA (females at 10 ppm
PQCl2) were considered to be related to dietary PQ exposure.Effects of paraquat on striatal and SNpc neurohistopathology
Dietary exposure to PQ for 4, 8, or 13 weeks did not cause any
gross or microscopic damage in any of the brain regions, from
the level of the frontal cortex through the striatum and midbrain,
including the SNpc. No morphologic changes attributed to PQ
exposure were noted with the stains/immunostains that were used
to evaluate neuronal cell death (Am Cu Ag), dopaminergic neurons/
processes (TH), astrocytic response (GFAP), microglial response
(IBA-1), apoptotic cell death (Caspase 3), nuclear changes (thio-
nine), or DNA fragmentation (TUNEL). Speciﬁcally, PQ exposure
was not associated with any neuronal, astrocytic, or microglial
changes in the substantia nigra or the striatum (Fig. 4). Representa-
tive photomicrographs are presented in Fig. 5.Effect of paraquat on SNpc TH+ neuronal cell number
There were no statistically-signiﬁcant effects of PQ in either
male or female mice on the number of TH+ neurons in the SNpc
after 13 weeks of dietary exposure, at either 10 or 50 ppm PQCl2
(Fig. 6).
Fig. 3. Mean striatal dopamine (DA), DOPAC, and HVA concentrations (ng/mg tissue) after 13 weeks of dietary treatment with PQCl2, or 7 days after the ip administration of
MPTP. DA turnover (expressed as a ratio) is estimated according to the following formula: DA turnover = ([HVA] + [DOPAC])/[DA]. Sample size (n) = 6 mice/sex/group except
for 10 ppm PQCl2 males (n = 5) and 50 ppm PQCl2 females (n = 5). ⁄p 6 0.05 ⁄⁄p 6 0.01.
254 D.J. Minnema et al. / Regulatory Toxicology and Pharmacology 68 (2014) 250–258Positive control – MPTP ip
MPTP effects on body weights, food consumption, and clinical
observations
MPTP caused a loss in mean body weight in males and females
over the week following MPTP administration. Hunched posture,
hypoactivity, piloerection, and/or tremors were observed with
increasing incidence, beginning at the time of the second MPTP
dose administration and continuing until after the fourth (ﬁnal)
dose.
Effects of MPTP on striatal neurochemistry
MPTP caused a statistically-signiﬁcant reduction in the striatal
concentration of dopamine and its metabolites, DOPAC and HVA,
and a statistically-signiﬁcant increase in dopamine turnover for
males, relative to controls (Fig. 3). The striatal concentration of
dopamine in female mice administered MPTP was reduced,
although this was not statistically signiﬁcant compared to controls.
Although HVA was statistically-signiﬁcantly decreased for the
MPTP-treated females, in the absence of corresponding changes
in DOPAC or dopamine turnover, it is unclear if this lower HVA
concentration is a reﬂection of MPTP treatment.
Effects of MPTP on striatal and SNpc neurohistopathology
Pathologic ﬁndings in the SNpc and/or striatum attributed to
MPTP included decreased TH immunostaining, increased GFAP
immunostaining, and increased IBA-1 immunostaining. Represen-
tative photomicrographs are presented in Fig. 5. Decreased TH
immunostaining, consistent with damage to the dopaminergic
neurons, was noted in the striatum of all MPTP-treated animals
(Fig. 4). Decreased TH immunostaining in the SNpc was noted for
3/5 males and none of the females. Decreased TH immunostaining
was also noted in the ventral tegmental area of the substantia nigra
for 3/5 males, but none of the females (data not shown). Increased
GFAP immunostaining, indicative of an increase in reactive astro-
cytes responding to the injury to synaptic terminals in the region,
was noted in the striatum for all MPTP-treated males and females.
In the SNpc, an increase in astrocyte staining was noted in only 1/5
males and 0/5 females. Increased IBA-1 immunostaining, indicative
of a reactive microglial response to tissue damage, was present
(severity grade 2/minimal) in the striatum of all males and females.
Although not shown in Fig. 5, the increased IBA-1 immunostainingnoted in the striatum following MPTP treatment was similar to
that shown previously (Breckenridge et al., 2013). Increased
IBA-1 immunostaining was present in the SNpc of 1/5 males and
0/5 females. Seven days after MPTP treatment, there was no
evidence of treatment effects in brain tissues stained/immuno-
stained with Am Cu Ag, Caspase 3, thionine, or TUNEL.
Effect of MPTP on SNpc TH+ neuronal cell count
The number of TH+ neurons in the SNpc was signiﬁcantly de-
creased (by 10%) in MPTP-treated male mice relative to controls.
No statistically-signiﬁcant effects of MPTP on the SNpc were ob-
served in female mice (Fig. 6).Discussion
Among the many studies in the literature that have examined
the potential effects of PQ on the SNpc, relatively few studies have
involved long-term continuous dosing. Prasad and colleagues
(Prasad et al., 2009) dosed PQ for up to 12 weeks to male mice
via drinking water, but only examined kinetics and measured no
endpoints related to neurotoxicity. Gollamudi and associates
(Gollamudi et al., 2012) administered PQCl2 to mice continuously
for seven days via subcutaneous mini-pumps at a dose of 10 mg/kg
bw/day prior to the assessment of TH+ neuronal cell loss and alpha-
synuclein immunoreactivity in the SNpc. A 35% reduction in TH+
counts in the SNpc was reported, but there was no increase in
alpha-synuclein immunoreactivity. No neuropathology or striatal
neurochemistry ﬁndings were reported. Ossowska et al. (2005)
administered PQ as repeated ip injections (10 mg/kg bw/injection)
to rats for up to 24 weeks, and reported a reduction in the number
of TH+ neurons in the SNpc and decreased [3H]-GBR binding to the
dopamine transporter in the caudate-putamen after 24 weeks of
treatment. No positive control was used in the (Ossowska et al.,
2005) study; previous studies have indicated that rats are rela-
tively insensitive to MPTP as compared to mice (Giovanni et al.,
1994). The relevance of these dose levels, routes, and durations
of exposure to human PQ exposure scenarios, and therefore to hu-
man risk assessment, is difﬁcult to assess.
In the current study, the potential effects on the nigrostriatal
dopaminergic system were assessed in male and female C57BL/6J
mice that were continuously exposed to PQ in the diet for 13 weeks
using neurochemistry, neuropathology, and stereology as toxico-
Fig. 4. Mean pathology scores for the striatum and SNpc, based on presence of silver positive staining (Am Cu Ag), decreased tyrosine hydroxylase staining, increased GFAP
staining, and increased IBA-1 staining after 4, 8, and 13 weeks of dietary treatment with PQ, or 7 days after the ip administration of MPTP. Mean severity scores (based on
numerical grading scores ranging from 0 [normal] to 5 [marked]) are based on 4 or 5 animals/sex/group at each assessment interval.
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2013).
The dietary kinetic study demonstrated that 90 days of dosing
was sufﬁcient to achieve a near steady-state concentration of PQ
in the brains of C57BL/6J mice, indicating that a longer duration
of treatment would not result in a measurably higher concentra-
tion of PQ in the brain (Figs. 1 and 2). The rate of PQ elimination
from the brain (half-life of approximately 21 days) following die-
tary dosing is consistent with previous reports from studies that
used the ip route (Breckenridge et al., 2013; Prasad et al., 2007,
2009). The predicted maximum concentration of PQ in the brain
in this dietary study at the 50 ppm dose level (416 and 655 ng
PQCl2/g tissue for males and females, respectively) was compara-
ble to that achieved previously with three weekly ip doses of 10 mg
PQCl2/kg bw (570 ng PQCl2/g tissue for males; Breckenridge et al.,
2013), a dosing regimen commonly used in PQ neurotoxicity stud-ies. In most cases, brain PQ concentrations have not been assessed
and/or reported in the literature where the potential damage to the
mouse SNpc has been investigated following repeated dosing with
PQ. Prasad et al. (2009) reported PQ concentrations in the striatum,
frontal cortex, hippocampus, and cerebellum following between 6
and 36 ip PQ doses (10 mg/kg bw/dose) at differing intervals as
being in the range 500-2000 ng/g tissue. In these studies the
authors reported neurochemical and other changes, and in some
cases PQ-related mortality. The PQ concentrations in the present
study at the high dietary dose (50 ppm) are within this concentra-
tion range, but at the lower end of it. It should be noted that since
our data are for whole brain PQ concentrations, any comparisons
should be made with caution. Although similar PQ concentrations
in the brain can be achieved both by dietary and ip dosing, the
dietary route is predicted to produce far less ﬂuctuation in plasma
PQ concentration than ip dosing, and therefore would more closely
Fig. 5. Photomicrographs from vehicle control mice, 50 ppm paraquat (PQ) mice (sacriﬁced after 4, 8, and 13 weeks of dietary exposure), and positive control (MPTP) mice. PQ
Mice: There are no morphologic changes in the striatum or the SNpc of the PQ mice; sections were indistinguishable from controls. MPTP Mice: [Tyrosine Hydroxylase
Staining (5A)]: There were notable decreases in TH+ staining of synaptic terminals in the striatum and neurons in the SNpc. Note the pale striatum area and the lack of a linear
area of dense TH+ staining representing the dopaminergic neurons of the SNpc. [GFAP Staining (5B)]: There is pronounced and diffuse astrocytosis (as indicated by increased
GFAP staining) in the striatum, relative to the normal level of astrocyte staining in the striatum, the SNpc, and the substantia nigra pars reticulata (SNpr). Note that astrocytes
are normally somewhat numerous in the SNpr. In the SNpc, there is a detectable linear increase of astrocyte staining in the SNpc, which is the thin layer immediately below
the SNpr. This staining indicates an increase of astrocytes/reactive astrocytes in the region of the SNpc, likely due to neuronal loss. [IBA-1 Staining (5C)]: The images are of the
SNpr (upper-left diagonal portion of the image). The area of the SNpc is not readily apparent, except in the image from the MPTP-treated animal, where there is a linear
increase of microglial cells (increased IBA-1 staining) in the SNpc.
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operators).
PQ was well tolerated by the C57BL/6J mice in the neurotoxicity
study, as indicated by only an initial transient reduction in body
weight gain at the top dose. Prolonged exposure to PQ via the diet
at 10 and 50 ppm PQCl2 did not result in a reduction in the number
of TH+ dopaminergic neurons in the SNpc; did not alter the concen-
tration of striatal dopamine or its metabolites; and did not produce
evidence of neuronal cell damage or glial activation.
Several previous PQ studies have used C57BL/6J male mice
(8–12 weeks of age) and multiple (typically three) ip administra-
tions of PQ. The doses used were typically 10 mg PQCl2 /kg bw/
dose occasion. Using this animal model, a number of laboratories
have observed a reduction in neuronal cell counts of dopaminergic
neurons in the SNpc following ip dosing (Brooks et al., 1999; Jiao
et al., 2012; McCormack et al., 2002). Our ip studies using neuropa-
thology, stereology, and speciﬁc stains for glial activation have
failed to replicate previously published ﬁndings, even with doses
of PQ approaching the maximum tolerated dose (25 mg PQCl2/kg
bw/dose by the ip route) (Breckenridge et al., 2013). In addition,
comprehensive neuropathological assessments (in which thepathologist was ‘‘blinded’’ to the source of the tissue) have consis-
tently indicated no evidence of neuronal cell damage, cell loss, or
an inﬂammatory response following PQ exposure by the ip route
(Breckenridge et al., 2013). As previously indicated (Breckenridge
et al., 2013), the reason for the discrepancy between these results
and those of several previously-published studies (Brooks et al.,
1999; Jiao et al., 2012; McCormack et al., 2002; Peng et al., 2004;
Yin et al., 2011) is not readily apparent. Jones et al. (2013) noted
that PQ-induced nigrostriatal loss is observed only in older mice
(generally greater than 3 months of age), and may be associated
with age-related iron accumulation in the ventral midbrain. In
the current dietary exposure study, the onset of PQ exposure oc-
curred at approximately 2.2 months of age and terminated at
approximately 5 months of age, suggesting that these mice should
be sensitive to PQ-induced neurotoxicity if age alone is the critical
factor in this exposure regimen. However, Jones et al. (2013) fur-
ther noted that PQ toxicity is a complex phenomenon, and that
‘‘not all individuals, or strains of mice, are likely to be equally sus-
ceptible to PQ neurotoxicity’’.
Employing the same methodology and similar endpoints as pre-
viously described, we now report that prolonged (13 week) dietary
Fig. 6. Number of tyrosine hydroxylase-positive (TH+) neurons in the substantia nigra pars compacta (SNpc) after 13 weeks of dietary treatment with PQ, or 7 days after the ip
administration of MPTP, as determined by stereology. Sample size (n) = 20 mice/sex/group, except for 50 ppm PQCl2 males (n = 19), MPTP males (n = 17), and 50 ppm PQCl2
females (n = 18). ⁄p 6 0.05.
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day (males and females, respectively) does not affect these neuro-
toxicity endpoints. These achieved dose levels are greater than the
no-observed-effect levels (NOELs) determined from a 90 day die-
tary mouse study (approximately 5 mg PQ ion/kg bodyweight/
day) and a 24 month dietary mouse study (approximately 2 mg
PQ ion/kg bw/day), based on lung and, in some cases, kidney ﬁnd-
ings, that are observed at higher dose levels (Joint Meeting on
Pesticide Residues [JMPR], 2003). The dose levels achieved in this
study are very signiﬁcantly (20x) higher than the dose levels cur-
rently used to derive protective toxicological reference doses for
operators and consumers (European Economic Community [EEC],
2003; Joint Meeting on Pesticide Residues [JMPR], 2003). These
toxicological reference doses are based on adverse respiratory sys-
tem ﬁndings in the dog following dietary exposure to PQ. There-
fore, the long established toxicological effects of PQ, and in
particular, the lung lesions caused by that tissue’s selective uptake
of PQ (Smith et al., 1990), remain the most sensitive endpoints
found in dietary studies. Consequently, the results from the pres-
ent study demonstrate that the sensitivity of the lung to PQ contin-
ues to be the most appropriate endpoint for determining the NOEL
used for deriving reference doses used in human risk assessment.
Treatment with MPTP (used as a positive control in this study)
resulted in decreased body-weight gain and clinical observations
consistent with the reported administration of MPTP (Jackson-Le-
wis and Przedborski, 2007). The neurochemistry, neurohistopa-
thology, and stereology ﬁndings in the male mice indicate that
MPTP damaged dopaminergic neurons in the SNpc and/or stria-
tum. The decrease in striatal dopamine concentrations in male
C57BL/6J mice following treatment with MPTP has been reported
by many investigators (Irwin et al., 1992; Reinhard et al., 1988).
Activation of microglia and astrocytes (as indicated by the in-
creased IBA-1 and GFAP immunostaining, respectively) are indica-
tive of a neuro-inﬂammatory response to cellular injury, which has
been observed following treatment with toxicants such as 6-
hydroxydopamine and MPTP (Herrera et al., 2000; Reinhard
et al., 1988; Sheng et al., 1993; Vila et al., 2001). The absence of
MPTP-induced changes in cupric silver staining (indicative of neu-
rodegenerative changes) in the current study is consistent with our
previous ﬁndings, in which increased Am Cu Ag staining peakedwithin 48 h of MPTP dosing, but was no longer observed at 168 h
(7 days) after dosing (Breckenridge et al., 2013). The peak of neuro-
nal necrosis in the SNpc is approximately 2–4 days after MPTP
administration (Switzer, 2011), whereas 7 days following MPTP
dosing, all evidence of neuronal (and synaptic terminal) disintegra-
tion is no longer detectable using the Am Cu Ag stain. The de-
creases in TH immunostaining noted histopathologically, as well
as the reduced number of TH+ neurons noted stereologically, in
male C57BL/6J mice following MPTP treatment are consistent with
many previous investigations (Jackson-Lewis and Smeyne, 2005).
In the current study, the extent of the reduction in TH+ neurons
in the SNpc following MPTP dosing was greater for male mice
when compared to female mice. The greater effect of MPTP in male
versus female mice on striatal dopamine concentrations is consis-
tent with previous ﬁndings (Miller et al., 1998). This sex difference
may be due to a protective estrogenic effect (Dluzen et al., 1996;
Shughrue, 2004).Conclusion
Exposure of mice to PQ via continuous dietary administration, a
paradigm which is more analogous to human exposure than the ip
administration route, resulted in a steady-state brain PQ concen-
tration by the end of the 13 week exposure period. No effects of
PQ on nigrostriatal dopaminergic processes, as assessed using neu-
rochemistry, stereology, and neuropathology, were noted in the
brains from male and female C57BL/6J mice administered PQCl2
in the diet at 50 ppm for 13 weeks (mean dose levels of 10.2 and
15.6 mg PQ ion/kg bw/day for males and females, respectively).
The expected damages to, and losses of, dopaminergic neurons,
as well as the anticipated reductions in striatal dopamine and its
metabolites, were observed following ip treatment with MPTP.Conﬂict of interest
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